| Assessment Status | Rapid Review Complete |
| HTA ID | 25071 |
| Drug | Alpha-1 proteinase inhibitor |
| Brand | Prolastin® |
| Indication | Alpha-1 proteinase inhibitor (Prolastin®) is indicated for long-term augmentation therapy in subjects with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes PiZZ, PiZ(null), Pi(null,null) and PiSZ). |
| Assessment Process | |
| Rapid review commissioned | 19/12/2025 |
| Rapid review completed | 13/01/2026 |
| Rapid review outcome | A full HTA is not recommended. On the basis of current evidence, the NCPE consider that A1PI (Prolastin®) not be considered for reimbursement*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here